

## **Microneedle-enhanced skin permeation of model dyes: Effect of the dye characteristics**

Gomaa YA<sup>a,b</sup>, El-Khordagui LK<sup>b</sup>, Garland MJ<sup>c</sup>, Donnelly RF<sup>c</sup>, McInnes F<sup>a</sup> & Wilson CG<sup>a</sup>.

<sup>a</sup> SIPBS, The John Arbuthnott Building, 27 Taylor Street, Strathclyde University, Glasgow G4 0NR

<sup>b</sup> Faculty of Pharmacy, Alexandria University, Egypt

<sup>c</sup> School of Pharmacy, Queens University, Belfast BT 97BL, Northern Ireland

**Introduction:** Microneedle arrays (MN) have been extensively investigated as a new technology permitting skin penetration of a wide variety of small drugs and macromolecules <sup>[1]</sup>. The mechanism of MN-mediated permeation enhancement has not been fully elucidated. Our aim was to assess the influence of the permeant physicochemical properties on MN-assisted skin permeation using a series of five structurally-related fluorescent dyes.

**Methods:** Dyes selected for the study were: Rhodamine B (Rh B, MW 479), Rhodamine B isothiocyanate (RITC, MW 536.1), Rhodamine B isothiocyanate dextran (RITC-D, MW 4.4 kDa), Tetramethyl-rhodamine B isothiocyanate dextran (TRITC-D, MW 10 kDa) and Fluorescein isothiocyanate (FITC, MW 389.4 Da). The effect of molecular weight, aqueous solubility and distribution/partition coefficients between n-octanol or skin and PBS <sup>[2]</sup> on permeation of dyes through full thickness pig skin pretreated with MN array (600 µm length and 121 MNs/array) was studied. For Rh B, both solid and dissolving MNs containing Rh B were tested.

**Results:** Skin permeation of the test dyes was negligible except for Rh B and FITC. MN-pretreatment enhanced skin permeation of both dyes only, and the flux being higher in case of Rh B (1.870 vs 0.187 µg/cm<sup>2</sup>/h for FITC). However, the use of dissolving MN reduced Rh B flux. Findings indicated that all physicochemical characteristics studied are important determinants of the solid MN-assisted skin permeation of the dyes as in the Potts and Guy model <sup>[3]</sup>.

<sup>[1]</sup> Donnelly RF, Singh TRR, Woolfson D. (2010). Drug Deliv. 17, 187-207.

<sup>[2]</sup> Chiang CH, Lai JS, Yang KH. (1991). Drug Dev. Ind. Pharm. 17, 91-111.

<sup>[3]</sup> Potts RO and Guy RH. (1992). Pharm. Res. 9, 663-669.